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Background
Defensins are natural peptides with potent anti-HIV activ-
ity. In humans two subfamilies exist, α- and β-defensins.
α-Defensins 1–3 are mainly secreted by neutrophils,
although other leukocytes also produce them. Besides
their direct antimicrobial effect, α-defensins 1–3 also exert
immunomodulory activities, chemoattracting leukocytes
and inducing cytokines and chemokines production. We
previously demonstrated that immature monocyte-
derived dendritic cells (MDDC produce and secrete α-
defensins 1–3 and that these defensins are able to modu-
late de maturation and differentiation of dendritic cells.
Methods
MDDC were generated in vitro from peripheral blood
from volunteer healthy controls (HC) and HIV-infected
patients, including elite controllers, viremic controllers,
untreated viremic noncontrollers and treated patients. To
determine α-defensins 1–3 production, culture superna-
tants were analyzed by ELISA and cells by real time RT-
PCR for mRNA expression.
Results
Immature MDDC from HIV-infected patients secreted sig-
nificantly higher levels of α-defensins 1–3 than HC (p <
0.0001). Within the HIV-infected group, this production
was statistically increased in untrated HIV-infected con-
trollers (p < 0.0001 vs HC) while in untreated viremic and
treated HIV-infected patients the production was not sig-
nificantly increased. The levels of α-defensins 1–3
secreted by immature MDDC positively correlated with
CD4 T cell counts in the controllers group (r = 0.59; p <
0.009), but not in viremic noncontrollers and treated
patients. No differences were observed in plasmatic α-
defensins 1–3 levels. HIV-infected patients with higher α-
defensins 1–3 secretion by immature MDDC showed a
slower disease progression, measured as no decrease in
the number of CD4+ T-cells below 350 cell/mm3 [HR =
8.9 (CI 1.2–65); p < 0.035], fewer increase in plasmatic
viral load [HR = 2.67 (CI 1.05–6.74; p < 0.04] and no ini-
tiation of treatment [HR = 10 (CI 1.02–98.2); p < 0.05]
along time.
Conclusion
Immature MDDC from HIV-infected patients who spon-
taneously control the infection produced higher levels of
α-defensins 1–3. This increased production of alpha-
defensins 1–3 was associated with a slower disease pro-
gression.
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